The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin ... Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

The two companies will carry out a phase 2 trial of Libtayo (cemiplimab ... It is one of five FixVacc vaccines in early-stage clinical testing, along with candidates for prostate, head and ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an ...